Nafarelin
- Generic Name
- Nafarelin
- Brand Names
- Synarel
- Drug Type
- Small Molecule
- Chemical Formula
- C66H83N17O13
- CAS Number
- 76932-56-4
- Unique Ingredient Identifier
- 1X0094V6JV
- Background
Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central precocious puberty and endometriosis.
- Indication
用于子宫内膜异位症、不育症等。
- Associated Conditions
- Central Precocious Puberty (CPP), Endometriosis
- Associated Therapies
- -
Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- New Hope Fertility Center
- Target Recruit Count
- 4
- Registration Number
- NCT02865681
- Locations
- 🇺🇸
New Hope Fertility Center, New York, New York, United States
Endometriosis : Traditional Medicine vs Hormone Therapy
Phase 1
Completed
- Conditions
- First Posted Date
- 2002-04-22
- Last Posted Date
- 2008-01-25
- Target Recruit Count
- 50
- Registration Number
- NCT00034047
- Locations
- 🇺🇸
Oregon Health Sciences University, Women's Health Research Unit, Portland, Oregon, United States
🇺🇸Oregon College of Oriental Medicine Clinic, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath